Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries

Abstract

ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.

Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review

“…After a detailed full-paper review, another eight were excluded. Thus nine studies were included in this review: seven cohort studies, of which one was a controlled cohort study,12–17 20 and two randomised clinical trials 18 19. Scanning references of included studies retrieved no additional articles.…”

“…Only TNFα inhibitors were used: infliximab in three articles,12 15 19 etanercept in two,18 20 adalimumab in one,16 and the above three TNF inhibitors considered as one group in three articles 13 14 17. Of the seven cohort studies, five studies were performed in a single country (UK, Germany or Sweden),12–15 17 and two were multinational studies (USA and Europe) 16 20. Four of the seven cohort studies were open-label extensions of an RCT,12 15 16 20 two were registers of biological agents14 17 and one was a retrospective study 13.…”

“…Of the seven cohort studies, five studies were performed in a single country (UK, Germany or Sweden),12–15 17 and two were multinational studies (USA and Europe) 16 20. Four of the seven cohort studies were open-label extensions of an RCT,12 15 16 20 two were registers of biological agents14 17 and one was a retrospective study 13. Of the two RCTs, one was a single country study (UK),18 and the other a multinational study (USA, Canada and Europe) 19.…”

“…In four of the seven cohort studies an inappropriate approach was used in the selection of study participants (selection bias) 12 15 17 20. Selective loss to follow-up was not appropriately accounted for in two cohort studies, and insufficiently reported in one 13 16 17.…”

“…Selective loss to follow-up was not appropriately accounted for in two cohort studies, and insufficiently reported in one 13 16 17. Four cohort studies did not adjust for potential confounders in the analysis 13 15 17 20. Four cohort studies did not report whether the work participation outcome could be attributed to AS, general health or another disease 14 15 17 20.…”